Gillian Woollett

Gillian Woollett, head of regulatory strategy and policy at Samsung Bioepis, shares her expertise on biosimilars regulation. She argues that streamlining FDA processes could cut development time and costs significantly. Woollett highlights the commercial challenges in the U.S., particularly the impact of pricing policies on investment in biosimilars. She also addresses the complexities of interchangeability and emphasizes the need for improved incentives to bolster market entry and competition for biosimilars.